LAIC
VRTX icon

Lederer & Associates Investment Counsel’s Vertex Pharmaceuticals VRTX Stock Holding History

Lederer & Associates Investment Counsel’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-5,943
Closed -$1.28M – 146
2021
Q1 		$1.28M Buy
5,943
+1,368
+30% +$300K 0.9% 45
2020
Q4 		$1.08M Sell
4,575
-2,342
-34% -$537K 0.83% 46
2020
Q3 		$1.88M Buy
6,917
+1,221
+21% +$337K 1.57% 24
2020
Q2 		$1.65M Buy
+5,696
New +$1.54M 1.55% 28

Other funds holding VRTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Lederer & Associates Investment Counsel's VRTX Position: Q2 2021 in Review

Lederer & Associates Investment Counsel sold out of Vertex Pharmaceuticals (VRTX) in Q2 2021, closing a stake of 5,943 shares — an estimated $1.28M sold.

Lederer & Associates Investment Counsel first reported a position in VRTX in Q2 2020 and held it in 4 quarters. The position peaked at $1.88M in Q3 2020. 977 funds tracked by Wall St. Rank hold VRTX as of Q2 2021.

  • Lederer & Associates Investment Counsel reported no remaining Vertex Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • Lederer & Associates Investment Counsel sold 5,943 Vertex Pharmaceuticals shares in Q2 2021, an estimated $1.28M.
  • Lederer & Associates Investment Counsel first reported a position in Vertex Pharmaceuticals in Q2 2020 and held it in 4 quarters.
  • Lederer & Associates Investment Counsel's Vertex Pharmaceuticals position peaked at $1.88M in Q3 2020.
  • 977 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2021.

Based on Lederer & Associates Investment Counsel's 13F filing for Q2 2021, filed 23 Jul 2021.